The difference between the origin of Alzheimer's disease (AD) and its symptoms is an obstacle to finding effective treatments ...

Bio-Techne Corp. plans to sell its Exosome Diagnostics Inc. business to Mdxhealth SA for $15 million plus royalty payments, a steep cut from the $250 million the company paid to acquire Exodx in 2018.

Jazz Pharmaceuticals plc is prepped and ready for launch following U.S. FDA accelerated approval of dordaviprone as the first systemic therapy for H3 K27M-mutant diffuse glioma. Branded Modeyso, the ...

Subtyping is what made precision medicine in cancer a reality. And for successful drug discovery in all its stages, finding ...